Chemical structure:

IUPAC name:

(S)-5-chloro-N-{[2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]oxazolidin-5-yl]methyl} thiophene-2-carboxamide

CAS number:

366789-02-8

Therapy area:

Anti-coagulant

References:

IH/USP/Ph.Eur

Status:

Under development

Mechanism of action

Both free and bound Factor Xa in the prothrombinase complex are inhibited by rivaroxaban.  It is a direct selective factor Xa inhibitor with a 2.5 to 4 hour start of action. Factor Xa inhibition prevents the intrinsic and extrinsic pathways of the blood coagulation cascade from working properly, preventing the production of thrombin and the growth of thrombi. Rivaroxaban has no impact on platelets and does not suppress thrombin (activated Factor II).

DISCLAIMER: PRODUCTS COVERED BY VALID & UNEXPIRED PATENTS ARE NOT OFFERED (OR) SUPPLIED FOR COMMERCIAL SCALE. THE PATENT POSITION SHOULD BE VERIFIED & LIABILITY LIES WITH THE CUSTOMER ONLY. PRODUCTS COVERED BY PATENTS ARE AVAILABLE ONLY FOR R&D USE.